实用肿瘤杂志2024，Vol.39Issue(6)：542-548,7.DOI:10.13267/j.cnki.syzlzz.2024.080
地舒单抗对比唑来膦酸治疗乳腺癌骨转移的疗效和安全性:一项倾向评分匹配队列研究
Efficacy and safety of denosumab versus zoledronic acid for treatment of bone metastasis in breast cancer patients:a propensity score-matched cohort study
黄香 1刘谦 1吴昕煜 1金楠 1殷咏梅1
作者信息
- 1. 南京医科大学第一附属医院肿瘤科,江苏 南京 210029
- 折叠
摘要
Abstract
Objective To compare the effectiveness and safety of denosumab versus zoledronic acid for the treatment of bone metasta-sis in patients with breast cancer.Methods The clinical data of 176 advanced breast cancer patients with bone metastasis treated with bone-modifying agents of denosumab(n=90)or zoledronic acid(n=86)in the Department of Oncology,the First Affiliated Hospital of Nan-jing Medical University from September 2020 to July 2022 was retrospectively analyzed.After 1∶1 propensity score matching,66 patients in denosumab group and 66 patients in zoledronic acid group were selected.The skeletal-related events(SREs)and adverse events in the denosumab group and the zoledronic acid group were evaluated.Results After a median follow-up of 18.3 months,the median time to first on-study SRE was not reached in neither the denosumab group nor the zoledronic acid group.The one-year SRE-free survival rate was 80.3%(95%CI:68.7%-89.1%)in the denosumab group,as compared with 63.6%(95%CI:50.9%-75.1%)in the zoledronic acid group.Denosumab reduced the risk of SREs(HR=0.48,95%CI:0.26-0.90,P=0.022).Adverse events were predominantly hypocalcemia in both groups,with a higher incidence of arthralgia in the zoledronic acid group(P=0.028).Conclusions Compared with zoledronic acid,denos-umab delayed the occurrence of SREs in advanced breast cancer patients with bone metastasis and had a lower incidence of arthralgia.关键词
乳腺癌/骨转移/骨改良药物/地舒单抗/唑来膦酸/骨相关事件Key words
breast cancer/bone metastasis/bone-modifying drug/denosumab/zoledronic acid/skeletal-related event引用本文复制引用
黄香,刘谦,吴昕煜,金楠,殷咏梅..地舒单抗对比唑来膦酸治疗乳腺癌骨转移的疗效和安全性:一项倾向评分匹配队列研究[J].实用肿瘤杂志,2024,39(6):542-548,7.
